This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Juntendo Educational Foundation, The University of Tokyo, Toudai Tlo, Ltd.. Active years: 2010-2018.
Location History:
- Tokyo, JP (2010 - 2014)
- Shinagawa-ku, JP (2018)
Company Filing History:
1 out of 24 
1 out of 1,355 
1 out of 41 Years Active: 2010-2018
Title: Kei Ohnuma: Innovator in Monoclonal Antibody Research
Introduction
Kei Ohnuma is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic agents targeting cancer. With a total of 3 patents to his name, Ohnuma's work focuses on innovative solutions for complex medical challenges.
Latest Patents
One of Ohnuma's latest patents is an anti-human CD26 monoclonal antibody or antigen-binding fragment thereof. This invention aims to provide an anti-human CD26 antibody that allows for the analysis of CD26 expression in cancer and immune tissues. It is designed to assist in selecting patients for treatment and monitoring therapeutic effects, and it can also be utilized in immunostaining. Another significant patent involves a method of treating malignant mesothelioma. This therapeutic agent comprises a substance that inhibits the binding of CD26 to the extracellular matrix, such as an siRNA targeting CD26 cDNA or an anti-CD26 antibody. The method includes administering this substance to patients in need of treatment.
Career Highlights
Throughout his career, Kei Ohnuma has worked with esteemed institutions, including the University of Tokyo and Juntendo Educational Foundation. His research has been pivotal in advancing the understanding and treatment of various cancers.
Collaborations
Ohnuma has collaborated with notable colleagues in his field, including Chikao Morimoto and Teruo Inamoto. Their combined expertise has contributed to the success of his innovative projects.
Conclusion
Kei Ohnuma's contributions to monoclonal antibody research and cancer treatment exemplify the impact of innovation in medicine. His patents reflect a commitment to improving patient outcomes through advanced therapeutic strategies.